Kura Oncology Stock News

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highl

Q1 2020 Kura Oncology Inc Earnings Call

SAN DIEGO, May 08, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the B

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwri

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an u

Joining me on the call from Kura are Dr. Troy Wilson, our President and Chief Executive Officer and Dr. Marc Grasso, our Chief Financial Officer and Chief Business Officer. Jim Basta, our Chief Legal

Q1 2020 Kura Oncology Inc Earnings Call

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financia

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Kura Oncology (NASDAQ:KURA) is scheduled to be posting its quarterly earnings results after the market closes on Monday, May 4th. Analysts expect Kura Oncology to post earnings of ($0.42) per share fo

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter

SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development...

Gainers Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares climbed 69.4% to close at $19.50 on Tuesday after the company presented positive preclinical and initial clinical data...